China National Accord Medicines Corporation Ltd.
The Third Quarterly Report for 2018
October 2018
Section I. Important Notice
Board of Directors Supervisory Committee all directors supervisors and senior
executives of China National Accord Medicines Corporation Ltd. (hereinafter
referred to as the Company) hereby confirm that there are no any fictitious
statements misleading statements or important omissions carried in this report
and shall take all responsibilities individual and/or joint for the reality accuracy
and completion of the whole contents.
All directors are present the meeting of the Board for deliberating the Third
Quarter Report of the Company in person.Lin Zhaoxiong person in charge of the Company head of the accounting works
Wei Pingxiao and Wang Ying accounting body principals (accountant in charge)
hereby confirm that the Financial Report of the Third Quarterly Report is
authentic accurate and complete.Section II. Basic information of Company
I. Main accounting data and index
Whether it has retroactive adjustment or re-statement on previous accounting data or not
□ Yes √ No
Current period-end Period-end of last year Increase/decrease
Total assets (RMB) 28244710026.77 22343643527.77 26.41%
Net assets attributable to
shareholders of listed company
(RMB)
11016212543.22 9396572345.88 17.24%
Current period
Increase/decrease in
comparison with same
period of last year
Year-begin to end of
the Period
Increase/decrease in
comparison with year-
begin to period-end of
last year
Operating revenue (RMB) 10987540368.77 2.17% 31766707068.44 1.56%
Net profit attributable to
shareholders of the listed company
(RMB)
285244535.54 15.49% 926971570.47 15.42%
Net profit attributable to
shareholders of the listed company
after deducting non-recurring gains
and losses (RMB)
282319350.57 15.27% 905615689.91 14.46%
Net cash flow arising from
operating activities (RMB)
-- -- 563991295.36 10.35%
Basic earnings per share
(RMB/Share)
0.666 15.42% 2.165 15.41%
Diluted earnings per share
(RMB/Share)
0.666 15.42% 2.165 15.41%
Weighted average ROE 2.62% 0.13 percent down 9.21% 0.06 percent up
Items and amount of extraordinary profit (gains)/losses
√Applicable □Not applicable
In RMB
Item
Amount from year-begin to
end of the Period
Note
Gains/losses from the disposal of non-current asset (including the
write-off that accrued for impairment of assets)
4361450.64
Account of property
expropriation received in the
period from government
Governmental subsidy reckoned into current gains/losses (not
including the subsidy enjoyed in quota or ration according to
national standards which are closely relevant to enterprise’s
business)
14437530.16
Received vary specific subsidy
and financial discount in the
period
Income from the exceeding part between investment cost of the
Company paid for obtaining subsidiaries associates and joint-
ventures and recognizable net assets fair value attributable to the
Company when acquiring the investment
729.29
Income from subsidiary-
Sinopharm Holding Guangzhou
Huadu Co. Ltd. acquisition in the
period
Reversal of impairment reserve for account receivable with
separate impairment testing
4292235.76
Net gain/loss of impairment
provision switch-back for
receivables
Gains/losses on entrusted loans 2398288.34
Income for providing entrust
loans to China National Zhijun
(Suzhou)
Other non-operating income and expenditure except for the
aforementioned items
2843762.60
Less: impact on income tax 6376396.25
Impact on minority shareholders’ equity (post-tax) 601719.98
Total 21355880.56 --
Concerning the extraordinary profit (gain)/loss defined by Q&A Announcement No.1 on Information Disclosure for Companies
Offering Their Securities to the Public --- Extraordinary Profit/loss and the items defined as recurring profit (gain)/loss according to
the lists of extraordinary profit (gain)/loss in Q&A Announcement No.1 on Information Disclosure for Companies Offering Their
Securities to the Public --- Extraordinary Profit/loss explain reasons
□ Applicable √ Not applicable
In reporting period the Company has no particular about items defined as recurring profit (gain)/loss according to the lists of
extraordinary profit (gain)/loss in Q&A Announcement No.1 on Information Disclosure for Companies Offering Their Securities to the
Public --- Extraordinary Profit/loss.II. Statement of the total shareholders and shares-held of top ten shareholders at end of the
Period
1. Total number of common shareholders at the end of this report period and top ten common shareholders
In Share
Total common shareholders at the
end of report period
18993
Total preference shareholders
with voting rights recovered at
end of reporting period (if
applicable)
0
Top ten shareholders
Shareholders Nature of Proportion of Amount of shares Amount of Number of share pledged/frozen
shareholder shares held held restricted shares
held
State of share Amount
Sinopharm Group
Co. Ltd.
State-owned
corporate
56.06% 239999991 55057700
HTHK/CMG
FSGUFP-CMG
FIRST STATE
CHINA
GROWTH FD
Overseas
corporate
2.37% 10141182
China Life
Insurance Co.Ltd. – tradition –
general insurance
products -005L-
CT001 Shen
Domestic non
state-owned
corporate
1.97% 8415792
China Insurance
– traditional
insurance
products
Domestic non
state-owned
corporate
1.42% 6092905
China National
Pharmaceutical
Foreign Trade
Corp.
State-owned
corporate
1.24% 5323043 5323043
National Social
Security Fund -
103
Domestic non
state-owned
corporate
1.17% 4999987
GUOTAI
JUNAN
SECURITIES(H
ONGKONG)
LIMITED
Overseas
corporate
1.03% 4396898
New China Life
Insurance
Company Ltd.
－Dividend －
individual
bonuses -018L-
FH002 Shen
Domestic non
state-owned
corporate
0.98% 4199772
#Beijing Hao
Qing Wealth
Investment
Management Co.
Domestic non
state-owned
corporate
0.96% 4118716
Ltd. –Hao Qing
Value Stable No.8
Investment Fund
UBS AG
LONDON
BRANCH
Overseas
corporate
0.90% 3833984
Particular about top ten shareholders with un-restrict shares held
Shareholders Amount of un-restrict shares held
Type of shares
Type Amount
Sinopharm Group Co. Ltd. 184942291
RMB ordinary
shares
184942291
HTHK/CMG FSGUFP-CMG FIRST
STATE CHINA GROWTH FD
10141182
Domestically
listed foreign
shares
10141182
China Life Insurance Co. Ltd. –
tradition –general insurance products
-005L-CT001 Shen
8415792
RMB ordinary
shares
8415792
China Insurance – traditional
insurance products
6092905
RMB ordinary
shares
6092905
National Social Security Fund -103 4999987
RMB ordinary
shares
4999987
GUOTAI JUNAN
SECURITIES(HONGKONG)
LIMITED
4396898
Domestically
listed foreign
shares
4396898
New China Life Insurance Company
Ltd. －Dividend －individual
bonuses -018L-FH002 Shen
4199772
RMB ordinary
shares
4199772
# Beijing Hao Qing Wealth
Investment Management Co. Ltd. –
Hao Qing Value Stable No.8
Investment Fund
4118716
RMB ordinary
shares
4118716
UBS AG LONDON BRANCH 3833984
Domestically
listed foreign
shares
3833984
China SAFE Investments Limited 3804400
RMB ordinary
shares
3804400
Explanation on associated
relationship among the aforesaid
shareholders
Sinopharm Group Co. Ltd. and China National Pharmaceutical Foreign Trade Corporation
have the same actual controller which is China National Pharmaceutical Group Corporation.It is unknown that there exists no associated relationship or belongs to the consistent actionist
among the other tradable shareholders regulated by the Management Measure of Information
Disclosure on Change of Shareholding for Listed Companies.
Explanation on top ten common
shareholders involving margin
business (if applicable)
Beijing Hao Qing Wealth Investment Management Co. Ltd. –Hao Qing Value Stable No.8
Investment Fund holds 4048216 shares of the Company through margin trading and
refinancing secured security account
Whether top ten common shareholders or top ten common shareholders with un-restrict shares held have a buy-back agreement dealing
in reporting period
□ Yes √ No
The shareholders of the Company have no buy-back agreement dealing in reporting period.
2. Total of shareholders with preferred stock held and the top ten shareholdings
□Applicable √Not applicable
Section III. Important events
I. Particular about major changes from items of main accounting statements and financial
indexes as well as reasons
√ Applicable □Not applicable
1. Cash and bank balances: increased 2792 million Yuan over that of year -begin with growth rate of 66.60% mainly because the
subsidiary Guoda Drugstore received strategic capital injection from strategic investor;
2. Note receivable: decreased 629 million Yuan over that of year -begin with growth rate of -41.85% mainly because note return
declined in the period;
3. Account receivable: increased 2861 million Yuan over that of year -begin with growth rate of 37.70% mainly because the business
development and more business increased as well as the repayment period increased;
4. Other current assets: decreased 28.7738 million Yuan over that of year-begin with growth rate of -36.45% mainly because more
non-deductible input tax occurred for large quantity of purchase at end of the year;
5. Total current assets: increased 5684 million Yuan over that of year-begin with growth rate of 31.03% mainly because the subsidiary
Guoda Drugstore received strategic capital injection from strategic investor;
6. Other equity instrument investment: increased 1400 million Yuan over that of year-begin with growth rate of 1022.96% mainly
because invested medical industry fund in the period;
7. Construction in progress: increased 16.6964 million Yuan over that of year-begin with growth rate of 72.76% mainly due to the
construction charge of ERP system;
8. Other non-current assets: decreased 68.7461 million Yuan over that of year-begin with growth rate of -48.41% mainly due to the
application of new financial instruments standards the medical industry fund was re-classified as other equity instrument investment;
9. Short-term loans: increased 626 million Yuan over that of year-begin with growth rate of 40.08% mainly because the supply chain
finance increased;
10. Other current liability: increased 46800 Yuan over that of year-begin with growth rate of 41.48% mainly because the amount of
sales tax to be sold increased over that of year-begin;
11. Long-term account payable: decreased 3.9437 million Yuan over that of year-begin with growth rate of -42.26% mainly because
the finance lease rent is paid in the period;
12. Non-controlling equity: increased 2005 million Yuan over that of year-begin with growth rate of 377.68% mainly because
subsidiary Guoda Drugstore received a capital-increase from strategy investor in the period;
13. Total owner’s equity: increased 3625 million Yuan over that of year-begin with growth rate of 36.51% mainly because subsidiary
Guoda Drugstore received a capital-increase from strategy investor in the period;
14. Assets impairment loss: decreased 1.8963 million Yuan over that of year-begin with growth rate of -123.65% mainly because the
previous year’s receivables with special accrual for bad debts has collected in the period;
15. Income from assets disposal: increased 4.3521 million Yuan on a y-o-y basis with growth rate of 78509.59% mainly because
received an account of property expropriation from government in the period;
16. Non-operation expenditure: decreased 6.1545 million Yuan on a y-o-y basis with growth rate of -73.92% mainly because the
penalty and reimbursement occurred in the period declined from a year earlier;
17. Gains/loss of minority shareholders: increased 20.1132 million Yuan on a y-o-y basis with growth rate of 31.74% mainly because
subsidiary Guoda Drugstore introduced strategic investor in the period thus the gains/loss of minority shareholders increased
correspondingly;
18. Total comprehensive income attributable to minority shareholders: increased 20.1132 million Yuan on a y-o-y basis with growth
rate of 31.74% mainly because subsidiary Guoda Drugstore introduced strategic investor in the period thus the total comprehensive
income attributable to minority shareholders increased correspondingly;
19. Write-back of tax received: decreased 5.8595 million Yuan on a y-o-y basis with growth rate of -77.36% mainly because the
received write-back of tax has decreased in the period;
20. Cash received with other operation activities concerned: increased 281 million Yuan on a y-o-y basis with growth rate of 126.76%
mainly because the quality and performance bond received in the period increased on a y-o-y basis;
21. Cash received from investment income: increased 70.7961 million Yuan on a y-o-y basis with growth rate of 117.67% mainly
because the interest received on entrusted loans from associated enterprise increased on a y-o-y basis in the period;
22. Net cash received from disposal of fixed assets intangible assets and other long-term assets: increased 5.1661 million Yuan on a
y-o-y basis with growth rate of 882.31% mainly because the revenue from intangible assets disposal increased on a y-o-y basis;
23. Subtotal of cash in-flow from investment activity: increased 77.9619 million Yuan on a y-o-y basis with growth rate of 48.72%
mainly because the interest received on entrusted loans from associated enterprise increased on a y-o-y basis in the period;
24. Net cash paid for acquiring subsidiary and other operation units: decreased 18.525 million Yuan on a y-o-y basis with growth rate
of -100.00% mainly because the equity amount are paid for subsidiary acquisition last period while no such amount occurred in the
period;
25. Other cash paid concerning investing activities: decreased 58.0525 million Yuan on a y-o-y basis with growth rate of -42.07%
mainly because the bill deposits have decreased in the period;
26. Net cash flow from investment activity: increased 136 million Yuan on a y-o-y basis with growth rate of 62.28% mainly because
the interest received on entrusted loans from associated enterprise increased on a y-o-y basis in the period;
27. Cash received from absorption of investment: increased 2778 million Yuan on a y-o-y basis with growth rate of 25385.25%
mainly because subsidiary Guoda Drugstore received strategic capital injection from strategy investor in the period;
28. Cash received from borrowing: decreased 247 million Yuan on a y-o-y basis with growth rate of -83.24% mainly because the
mobile loans received from the bank declined on a y-o-y basis;
29. Subtotal of cash in-flow from financing activity: increased 2537 million Yuan on a y-o-y basis with growth rate of 618.25%
mainly because subsidiary Guoda Drugstore received strategic capital injection from strategy investor in the period;
30. Cash paid for debts: decreased 210 million Yuan on a y-o-y basis with growth rate of -72.54% mainly because the cash paid for
debts declined on a y-o-y basis for change of the bank deposit in the period;
31. Cash paid with other financing activity concerned: decreased 127 million Yuan on a y-o-y basis with growth rate of -67.67%
mainly because the factoring commission and interest on financial leasing paid in the period declined on a y-o-y basis;
32. Subtotal of cash out-flow from financing activity: decreased 316 million Yuan on a y-o-y basis with growth rate of -43.11%
mainly because the cash paid for debts declined on a y-o-y basis for change of the bank deposit in the period;
33. Net cash flow from financing activity: increased 2853 million Yuan on a y-o-y basis with growth rate of 884.55% mainly because
subsidiary Guoda Drugstore received strategic capital injection from strategy investor in the period;
34. Influence on cash and cash equivalent caused by fluctuations in exchange: decreased 314500 Yuan on a y-o-y basis with growth
rate of -100.00% mainly caused by the exchange rate conversion for dividend payout of B-share in HK dollar;
35. Net increase of cash and cash equivalent: increased 3042 million Yuan on a y-o-y basis with growth rate of 10257.11% mainly
because subsidiary Guoda Drugstore received strategic capital injection from strategy investor in the period;
36. Balance of cash and cash equivalent at period-end: increased 3564 million Yuan on a y-o-y basis with growth rate of 114.19%
mainly because subsidiary Guoda Drugstore received strategic capital injection from strategy investor in the period.II. Progress and influence of the main events as well as solution analysis specification
□ Applicable √ Not applicable
III. Commitments that the company shareholders actual controller offeror directors
supervisors senior management or other related parties have fulfilled during the reporting
period and have not yet fulfilled by the end of reporting period
□ Applicable √ Not applicable
There are no commitments that the company shareholders actual controller offeror directors supervisors senior management or other
related parties have fulfilled during the reporting period and have not yet fulfilled by the end of reporting period.IV. Estimation of operation performance for year of 2018
Estimation on accumulative net profit from the beginning of the year to the end of next report period to be loss probably or the warning
of its material change compared with the corresponding period of the last year and explanation on reason
□ Applicable √ Not applicable
V. Particular about security investment
□ Applicable √ Not applicable
The Company had no security investment in Period.VI. Trust financing
□ Applicable √ Not applicable
The Company had no trust financing in Period.VII. Particulars about derivatives investment
□ Applicable √ Not applicable
The Company had no derivatives investment in Period.VIII. Registration form of receiving research communication and interview in the report
period
□Applicable √ Not applicable
The Company has no research communication and interview accepted in the Period.IX. Guarantee outside against the regulation
□Applicable √Not applicable
The Company had no guarantee outside against the regulation in the reporting period.X. Non-operational fund occupation from controlling shareholders and its related party
□ Applicable √ Not applicable
The Company had no non-operational fund occupation from controlling shareholders and its related party.Section IV. Financial Statement
I. Financial statement
1. Consolidate balance sheet
Prepared by China National Accord Medicines Corporation Ltd.
2018-09-30
In RMB
Item Balance at period-end Balance at period-begin
Current assets:
Cash and bank balances 6983234857.70 4191655438.51
Settlement provisions
Capital lent
Transactional financial assets
Derivative financial assets
Notes receivable and accounts
receivable
11325059730.25 9093607443.96
Including: Notes receivable 874740558.07 1504194764.08
Accounts receivable 10450319172.18 7589412679.88
Advances to suppliers 463638268.60 516778117.47
Insurance receivable
Reinsurance receivables
Contract reserve of reinsurance
receivable
Other receivables 543343748.58 657932499.65
Purchase restituted finance asset
Inventories 4639692765.59 3781858238.12
Contractual assets
Assets held for sale
Non-current asset due within one year
Other current assets 50173873.93 78947644.62
Total current assets 24005143244.65 18320779382.33
Non-current assets:
Loans and payments on behalf
Investment in creditor’s rights
Other investment in creditor’s rights
Long-term account receivable
Long-term equity investment 1782914509.18 1650619373.09
Other equity instruments investment 153685760.00 13685760.00
Other non current financial assets
Investment property 143416634.53 153678339.11
Fixed assets 556542495.67 551710434.02
Construction in progress 39643659.20 22947258.99
Productive biological asset
Oil and gas asset
Intangible assets 310687053.16 325751430.88
Expense on Research and
Development
Goodwill 830729152.75 830729152.75
Long-term prepaid expenses 266030743.26 252247050.79
Deferred income tax asset 82640420.15 79472883.06
Other non-current asset 73276354.22 142022462.75
Total non-current asset 4239566782.12 4022864145.44
Total assets 28244710026.77 22343643527.77
Current liabilities:
Short-term loans 2187210613.46 1561354521.64
Loan from central bank
Absorbing deposit and interbank
deposit
Capital borrowed
Transactional financial liabilities
Derivative financial liability
Notes payable and accounts payable 10511611711.71 8876658828.52
Advances from customers 184636672.94 216938239.32
Contract liabilities
Selling financial asset of repurchase
Commission charge and commission
payable
Payable to employee 192940541.14 215656526.54
Taxes payable 194484692.28 223752900.24
Other accounts payable 1136010493.24 1030329660.02
Reinsurance payables
Insurance contract reserve
Security trading of agency
Security sales of agency
Liability held for sale
Non-current liabilities due within 1
year
5755080.19 5434770.70
Other current liabilities 159609.75 112817.65
Total current liabilities 14412809414.71 12130238264.63
Non-current liabilities:
Long-term loans 31600000.00 31600000.00
Bonds payable
Including: preferred stock
Perpetual capital securities
Long-term account payable 5388881.21 9332537.14
Long-term Payable to employee 1636000.00 1777000.00
Projected liabilities
Deferred income 122453251.86 125082372.53
Deferred income tax liabilities 72212487.72 71883253.02
Other non-current liabilities 46227343.31 46227343.31
Total non-current liabilities 279517964.10 285902506.00
Total liabilities 14692327378.81 12416140770.63
Owner’s equity:
Share capital 428126983.00 428126983.00
Other equity instrument
Including: preferred stock
Perpetual capital securities
Capital surplus 4002535786.76 3181429064.99
Less: Inventory shares
Other comprehensive income
Reasonable reserve
Surplus reserve 214063491.50 214063491.50
Provision of general risk
Retained earnings 6371486281.96 5572952806.39
Shareholders’ equity attributable to
shareholders of parent company
11016212543.22 9396572345.88
Non-controlling interests 2536170104.74 530930411.26
Total owner’s equity 13552382647.96 9927502757.14
Total liabilities and owner’s equity 28244710026.77 22343643527.77
Legal representative: Lin Zhaoxiong
Person in charge of accounting works: Wei Pingxiao
Person in charge of accounting institution: Wang Ying
2. Balance Sheet of Parent Company
In RMB
Item Balance at period-end Balance at period-begin
Current assets:
Cash and bank balances 1644584431.40 1776696342.87
Transactional financial assets
Derivative financial assets
Notes receivable and accounts
receivable
707800384.53 545267378.99
Including: Notes receivable 16596621.54 64799618.07
Accounts receivable 691203762.99 480467760.92
Advances to suppliers 2213378.98 1138312.26
Other receivables 1403855929.94 1517882239.81
Inventories 179871213.92 172022676.96
Contractual assets
Assets held for sale
Non-current assets maturing within one
year
Other current assets 39482.38 788964.90
Total current assets 3938364821.15 4013795915.79
Non-current assets:
Investment in creditor’s rights
Other investment in creditor’s rights
Long-term receivables
Long-term equity investments 7329323360.05 7180306084.56
Other equity instruments investment 140000000.00
Other non-current financial assets
Investment property 2157848.81 2763831.92
Fixed assets 20156870.46 13831103.54
Construction in progress
Productive biological assets
Oil and natural gas assets
Intangible assets 1497529.30 1287775.78
Research and development costs
Goodwill
Long-term prepaid expenses 4726014.47 5543217.86
Deferred income tax assets 3248549.21 2764724.75
Other non-current assets 7000000.00 71808611.00
Total non-current assets 7508110172.30 7278305349.41
Total assets 11446474993.45 11292101265.20
Current liabilities:
Short-term loans 664000000.00 707000000.00
Transactional financial liabilities
Derivative financial liability
Notes payable and accounts payable 714750735.49 674450646.65
Advances from customers 984581.64 1912503.90
Contract liabilities
Payable to employee 28883832.34 33592851.93
Taxes payable 7469386.55 42386907.00
Other accounts payable 1081738486.24 1415723188.96
Liability held for sale
Non-current liabilities due within 1
year
Other current liabilities 159609.75 112817.65
Total current liabilities 2497986632.01 2875178916.09
Non-current liabilities:
Long-term loans 31600000.00 31600000.00
Bonds payable
Including: preferred stock
Perpetual capital securities
Long-term account payable 800000.00 800000.00
Long-term Payable to employee
Projected liabilities
Deferred income 1756431.56 2054250.00
Deferred income tax liabilities 4749282.38 3773319.00
Other non-current liabilities
Total non-current liabilities 38905713.94 38227569.00
Total liabilities 2536892345.95 2913406485.09
Owners’ equity:
Share capital 428126983.00 428126983.00
Other equity instrument
Including: preferred stock
Perpetual capital securities
Capital surplus 4407519808.63 4407091484.13
Less: Inventory shares
Other comprehensive income
Reasonable reserve
Surplus reserve 214063491.50 214063491.50
Retained earnings 3859872364.37 3329412821.48
Total owner’s equity 8909582647.50 8378694780.11
Total liabilities and owner’s equity 11446474993.45 11292101265.20
3. Consolidated Profit Statement (the period)
In RMB
Item Current Period Last Period
I. Total operating income 10987540368.77 10753911112.98
Including: Operating income 10987540368.77 10753911112.98
Interest income
Insurance gained
Commission charge and
commission income
II. Total operating cost 10672350613.96 10476330643.94
Including: Operating cost 9749853630.20 9652629532.14
Interest expense
Commission charge and
commission expense
Cash surrender value
Net amount of expense of
compensation
Net amount of withdrawal of
insurance contract reserve
Bonus expense of guarantee slip
Reinsurance expense
Taxes and surcharges 30175966.21 27755633.18
Sales expenses 682736449.56 576266856.55
Administration expenses 188693332.32 183065386.00
R&D expenses
Financial expenses 20736052.88 35176387.62
Including: Interest expenses 45676535.07 40724369.96
Interest income 26253068.71 8547239.22
Losses of devaluation of asset 155182.79 1436848.45
Credit impairment loss
Add: other income 1815373.95 4885408.95
Investment income (Loss is listed
with “-”)
78983284.46 54961155.07
Including: Investment income on
affiliated company and joint venture
78933284.46 54961155.07
Net exposure hedging
benefits (Loss is listed with “-”)
Changing income of fair
value(Loss is listed with “-”)
Exchange income (Loss is listed
with “-”)
Income from assets disposal (Loss
is listed with “-”)
76479.50 -479542.26
III. Operating profit (Loss is listed
with “-”)
396064892.72 336947490.80
Add: Non-operating income 1553611.12 3013969.77
Less: Non-operating expense 374027.37 4765878.32
IV. Total Profit (Loss is listed with
“-”)
397244476.47 335195582.25
Less: Income tax expense 76038019.79 68255324.72
V. Net profit (Net loss is listed with “-”) 321206456.68 266940257.53
(i) net profit from continuous
operation (Net loss is listed with “-”)
321206456.68 266940257.53
(ii) net profit from discontinued
operation (Net loss is listed with “-”)
Net profit attributable to owner’s of
parent company
285244535.54 246977990.75
Minority shareholders’ gains and
losses
35961921.14 19962266.78
VI. Net after-tax of other
comprehensive income
Net after-tax of other comprehensive
income attributable to owners of parent
company
(I) Other comprehensive income
items which will not be reclassified
subsequently to profit of loss
1. Changes as a result of re-
measurement of net defined benefit plan
liability or asset
2. Share of the other
comprehensive income of the investee
accounted for using equity method
which will not be reclassified
subsequently to profit and loss
3. Change of the fair value
of other equity instrument investment
4.Change of the fair value
of enterprise’s own credit risk
5. Other
(II) Other comprehensive income
items which will be reclassified
subsequently to profit or loss
1. Share of the other
comprehensive income of the investee
accounted for using equity method
which will be reclassified subsequently
to profit or loss
2. Change of fair value of
other debt investment
3.Amount of financial
assets re-classified to other
comprehensive income
4.Credit impairment
provision for other debt investment
5.Cash flow hedging
reserve
6. Translation differences
arising on translation of foreign
currency financial statements
7. Other
Net after-tax of other comprehensive
income attributable to minority
shareholders
VII. Total comprehensive income 321206456.68 266940257.53
Total comprehensive income
attributable to owners of parent
Company
285244535.54 246977990.75
Total comprehensive income
attributable to minority shareholders
35961921.14 19962266.78
VIII. Earnings per share:
(i) Basic earnings per share 0.666 0.577
(ii) Diluted earnings per share 0.666 0.577
As for the business merger under the same control in the Period 0 Yuan net profit realized before merger by the
combined party the net profit for combined party in last period was 0 Yuan.Legal representative: Lin Zhaoxiong
Person in charge of accounting works: Wei Pingxiao
Person in charge of accounting institution: Wang Ying
4. Profit Statement of Parent Company (the period)
In RMB
Item Current Period Last Period
I. Operating income 899859002.45 900080112.15
Less: Operating cost 856296603.88 869401788.37
Taxes and surcharges 1445734.44 784481.12
Sales expenses 16953141.79 12874352.60
Administration expenses 16785749.55 16582316.33
R&D expenses
Financial expenses -10270272.65 -6369097.36
Including: Interest expenses 10951050.33 5184109.36
Interest income 21345942.02 11829749.52
Losses of devaluation of asset -152059.06 117780.84
Credit impairment loss
Add: other income 121990.82
Investment income (Loss is
listed with “-”)
84991405.06 63018807.05
Including: Investment income
on affiliated company and joint venture
84991405.06 60919200.32
Net exposure hedging
benefits (Loss is listed with “-”)
Changing income of fair
value(Loss is listed with “-”)
Income from assets disposal (Loss
is listed with “-”)
11116.50
II. Operating profit (Loss is listed
with “-”)
103924616.88 69707297.30
Add: Non-operating income 3.98 3387.55
Less: Non-operating expense 850000.01
III. Total Profit (Loss is listed with
“-”)
103924620.86 68860684.84
Less: Income tax expense 4806491.84 1455763.24
IV. Net profit (Net loss is listed with
“-”)
99118129.02 67404921.60
(i) net profit from continuous
operation (Net loss is listed with “-”)
99118129.02 67404921.60
(ii) net profit from discontinued
operation (Net loss is listed with “-”)
V. Net after-tax of other comprehensive
income
(I) Other comprehensive income
items which will not be reclassified
subsequently to profit of loss
1. Changes as a result of re-
measurement of net defined benefit plan
liability or asset
2. Share of the other
comprehensive income of the investee
accounted for using equity method
which will not be reclassified
subsequently to profit and loss
3. Change of the fair value
of other equity instrument investment
4.Change of the fair value
of enterprise’s own credit risk
5. Other
(II) Other comprehensive income
items which will be reclassified
subsequently to profit or loss
1. Share of the other
comprehensive income of the investee
accounted for using equity method
which will be reclassified subsequently
to profit or loss
2. Change of fair value of
other debt investment
3.Amount of financial
assets re-classified to other
comprehensive income
4.Credit impairment
provision for other debt investment
5.Cash flow hedging
reserve
6. Translation differences
arising on translation of foreign
currency financial statements
7. Other
VI. Total comprehensive income 99118129.02 67404921.60
VII. Earnings per share:
(i) Basic earnings per share
(ii) Diluted earnings per share
5. Consolidated Profit Statement (form the year-begin to the period-end)
In RMB
Item Current Period Last Period
I. Total operating income 31766707068.44 31278718782.55
Including: Operating income 31766707068.44 31278718782.55
Interest income
Insurance gained
Commission charge and
commission income
II. Total operating cost 30779047376.24 30399229240.83
Including: Operating cost 28117497354.04 28016663982.97
Interest expense
Commission charge and
commission expense
Cash surrender value
Net amount of expense of
compensation
Net amount of withdrawal of
insurance contract reserve
Bonus expense of guarantee slip
Reinsurance expense
Taxes and surcharges 86796493.46 90941254.04
Sales expenses 1956325205.63 1686713794.72
Administration expenses 540513396.10 523701437.11
R&D expenses
Financial expenses 78277597.20 79675166.38
Including: Interest expenses 129032902.25 100292883.44
Interest income 49335302.27 26007610.64
Losses of devaluation of asset -362670.19 1533605.61
Credit impairment loss
Add: other income 12404586.52 12843902.62
Investment income (Loss is listed
with “-”)
241677055.81 201687194.97
Including: Investment income on
affiliated company and joint venture
241595555.81 201637194.97
Net exposure hedging
benefits (Loss is listed with “-”)
Changing income of fair
value(Loss is listed with “-”)
Exchange income (Loss is listed
with “-”)
Income from assets disposal (Loss
is listed with “-”)
4357644.11 5543.40
III. Operating profit (Loss is listed
with “-”)
1246098978.64 1094026182.71
Add: Non-operating income 7052562.23 9070112.60
Less: Non-operating expense 2171320.17 8325866.41
IV. Total Profit (Loss is listed with
“-”)
1250980220.70 1094770428.90
Less: Income tax expense 240524754.11 228296432.35
V. Net profit (Net loss is listed with “-”) 1010455466.59 866473996.55
(i) net profit from continuous
operation (Net loss is listed with “-”)
1010455466.59 866473996.55
(ii) net profit from discontinued
operation (Net loss is listed with “-”)
Net profit attributable to owner’s of
parent company
926971570.47 803103308.94
Minority shareholders’ gains and
losses
83483896.12 63370687.61
VI. Net after-tax of other
comprehensive income
Net after-tax of other comprehensive
income attributable to owners of parent
company
(I) Other comprehensive income
items which will not be reclassified
subsequently to profit of loss
1. Changes as a result of re-
measurement of net defined benefit plan
liability or asset
2. Share of the other
comprehensive income of the investee
accounted for using equity method
which will not be reclassified
subsequently to profit and loss
3. Change of the fair value
of other equity instrument investment
4.Change of the fair value
of enterprise’s own credit risk
5. Other
(II) Other comprehensive income
items which will be reclassified
subsequently to profit or loss
1. Share of the other
comprehensive income of the investee
accounted for using equity method
which will be reclassified subsequently
to profit or loss
2. Change of fair value of
other debt investment
3.Amount of financial
assets re-classified to other
comprehensive income
4.Credit impairment
provision for other debt investment
5.Cash flow hedging
reserve
6. Translation differences
arising on translation of foreign
currency financial statements
7. Other
Net after-tax of other comprehensive
income attributable to minority
shareholders
VII. Total comprehensive income 1010455466.59 866473996.55
Total comprehensive income
attributable to owners of parent
Company
926971570.47 803103308.94
Total comprehensive income
attributable to minority shareholders
83483896.12 63370687.61
VIII. Earnings per share:
(i) Basic earnings per share 2.165 1.876
(ii) Diluted earnings per share 2.165 1.876
As for the business merger under the same control in the Period 0 Yuan net profit realized before merger by the
combined party the net profit for combined party in last period was 0 Yuan.
6. Profit Statement of Parent Company (form the year-begin to the period-end)
In RMB
Item Current Period Last Period
I. Operating income 2587480358.28 2558680931.11
Less: Operating cost 2471014077.79 2470049377.83
Taxes and surcharges 3462103.37 5846798.28
Sales expenses 42847937.24 35718966.89
Administration expenses 50464856.30 41500304.54
R&D expenses
Financial expenses -29640152.73 -43412064.91
Including: Interest expenses 31721163.76 10323519.88
Interest income 62271142.76 54307313.03
Losses of devaluation of asset 471483.25 85176.13
Credit impairment loss
Add: other income 1421335.96 641300.00
Investment income (Loss is
listed with “-”)
619832149.52 571379548.90
Including: Investment income
on affiliated company and joint venture
258317695.20 216757940.77
Net exposure hedging
benefits (Loss is listed with “-”)
Changing income of fair
value(Loss is listed with “-”)
Income from assets disposal (Loss
is listed with “-”)
11116.50 1087.38
II. Operating profit (Loss is listed
with “-”)
670124655.04 620914308.63
Add: Non-operating income 37.06 187919.51
Less: Non-operating expense 127688.63 1861760.16
III. Total Profit (Loss is listed with
“-”)
669997003.47 619240467.98
Less: Income tax expense 11099365.68 23311778.81
IV. Net profit (Net loss is listed with
“-”)
658897637.79 595928689.17
(i) net profit from continuous
operation (Net loss is listed with “-”)
658897637.79 595928689.17
(ii) net profit from discontinued
operation (Net loss is listed with “-”)
V. Net after-tax of other comprehensive
income
(I) Other comprehensive income
items which will not be reclassified
subsequently to profit of loss
1. Changes as a result of re-
measurement of net defined benefit plan
liability or asset
2. Share of the other
comprehensive income of the investee
accounted for using equity method
which will not be reclassified
subsequently to profit and loss
3. Change of the fair value
of other equity instrument investment
4. Change of the fair value
of enterprise’s own credit risk
5. Other
(II) Other comprehensive income
items which will be reclassified
subsequently to profit or loss
1. Share of the other
comprehensive income of the investee
accounted for using equity method
which will be reclassified subsequently
to profit or loss
2. Change of fair value of
other debt investment
3. Amount of financial
assets re-classified to other
comprehensive income
4. Credit impairment
provision for other debt investment
5. Cash flow hedging
reserve
6. Translation differences
arising on translation of foreign
currency financial statements
7. Other
VI. Total comprehensive income 658897637.79 595928689.17
VII. Earnings per share:
(i) Basic earnings per share
(ii) Diluted earnings per share
7. Consolidated Cash Flow Statement (form the year-begin to the period-end)
In RMB
Item Current Period Last Period
I. Cash flows arising from operating
activities:
Cash received from selling
commodities and providing labor
services
33576126717.79 33680871791.23
Net increase of customer deposit
and interbank deposit
Net increase of loan from central
bank
Net increase of capital borrowed
from other financial institution
Cash received from original
insurance contract fee
Net cash received from reinsurance
business
Net increase of insured savings and
investment
Net increase of amount from
disposal financial assets that measured
by fair value and with variation
reckoned into current gains/losses
Cash received from interest
commission charge and commission
Net increase of capital borrowed
Net increase of returned business
capital
Write-back of tax received 1714760.21 7574262.64
Other cash received concerning
operating activities
503409429.80 222004857.99
Subtotal of cash inflow arising from
operating activities
34081250907.80 33910450911.86
Cash paid for purchasing
commodities and receiving labor service
30058268141.08 30272872617.59
Net increase of customer loans and
advances
Net increase of deposits in central
bank and interbank
Cash paid for original insurance
contract compensation
Cash paid for interest commission
charge and commission
Cash paid for bonus of guarantee
slip
Cash paid to/for staff and workers 1392220211.12 1266243435.50
Taxes paid 818864295.31 861250651.49
Other cash paid concerning
operating activities
1247906964.93 999000769.40
Subtotal of cash outflow arising from
operating activities
33517259612.44 33399367473.98
Net cash flows arising from operating
activities
563991295.36 511083437.88
II. Cash flows arising from investing
activities:
Cash received from recovering
investment
Cash received from investment
income
130963345.37 60167262.76
Net cash received from disposal of
fixed intangible and other long-term
assets
5751674.16 585524.78
Net cash received from disposal of
subsidiaries and other units
Other cash received concerning
investing activities
101261607.73 99261955.41
Subtotal of cash inflow from investing
activities
237976627.26 160014742.95
Cash paid for purchasing fixed
intangible and other long-term assets
150353192.93 126571984.56
Cash paid for investment 90000000.00 95137145.33
Net increase of mortgaged loans
Net cash received from
subsidiaries and other units obtained
18525000.00
Other cash paid concerning
investing activities
79921476.82 137974010.61
Subtotal of cash outflow from investing
activities
320274669.75 378208140.50
Net cash flows arising from investing
activities
-82298042.49 -218193397.55
III. Cash flows arising from financing
activities
Cash received from absorbing
investment
2788851200.00 10943000.00
Including: Cash received from
absorbing minority shareholders’
investment by subsidiaries
2788851200.00 10943000.00
Cash received from loans 49670200.30 296311793.77
Cash received from issuing bonds
Other cash received concerning
financing activities
108949307.54 103113564.29
Subtotal of cash inflow from financing
activities
2947470707.84 410368358.06
Cash paid for settling debts 79670200.30 290130072.33
Cash paid for dividend and profit
distributing or interest paying
276628059.98 255153017.01
Including: Dividend and profit of
minority shareholder paid by
subsidiaries
56858945.30 36992199.01
Other cash paid concerning
financing activities
60658096.82 187628354.86
Subtotal of cash outflow from financing
activities
416956357.10 732911444.20
Net cash flows arising from financing
activities
2530514350.74 -322543086.14
IV. Influence on cash and cash
equivalents due to fluctuation in
exchange rate
-314517.97
V. Net increase of cash and cash 3011893085.64 -29653045.81
equivalents
Add: Balance of cash and cash
equivalents at the period -begin
3673498691.48 3150909425.54
VI. Balance of cash and cash
equivalents at the period -end
6685391777.12 3121256379.73
8. Cash Flow Statement of Parent Company (form the year-begin to the period-end)
In RMB
Item Current Period Last Period
I. Cash flows arising from operating
activities:
Cash received from selling
commodities and providing labor
services
2681236630.70 2597564040.32
Write-back of tax received
Other cash received concerning
operating activities
91958196.80 26424030.63
Subtotal of cash inflow arising from
operating activities
2773194827.50 2623988070.95
Cash paid for purchasing
commodities and receiving labor
service
2559377589.52 2572754403.03
Cash paid to/for staff and workers 61913310.95 56647266.92
Taxes paid 29801808.96 39084840.35
Other cash paid concerning
operating activities
45140599.54 25300370.50
Subtotal of cash outflow arising from
operating activities
2696233308.97 2693786880.80
Net cash flows arising from operating
activities
76961518.53 -69798809.85
II. Cash flows arising from investing
activities:
Cash received from recovering
investment
Cash received from investment
income
255904643.39 216058026.83
Net cash received from disposal of
fixed intangible and other long-term
35200.00
assets
Net cash received from disposal of
subsidiaries and other units
Other cash received concerning
investing activities
1218035586.01 2156269200.00
Subtotal of cash inflow from investing
activities
1473975429.40 2372327226.83
Cash paid for purchasing fixed
intangible and other long-term assets
8607026.77 6871001.07
Cash paid for investment 90000000.00 1045900000.00
Net cash received from subsidiaries
and other units
18525000.00
Other cash paid concerning
investing activities
1267321606.82 1691189918.90
Subtotal of cash outflow from investing
activities
1365928633.59 2762485919.97
Net cash flows arising from investing
activities
108046795.81 -390158693.14
III. Cash flows arising from financing
activities
Cash received from absorbing
investment
Cash received from loans 10000000.00 41600000.00
Cash received from issuing bonds
Other cash received concerning
financing activities
12559913378.52 11644239507.12
Subtotal of cash inflow from financing
activities
12569913378.52 11685839507.12
Cash paid for settling debts 10000000.00 41600000.00
Cash paid for dividend and profit
distributing or interest paying
153116428.79 146079007.62
Other cash paid concerning
financing activities
12723602657.57 11231111506.09
Subtotal of cash outflow from financing
activities
12886719086.36 11418790513.71
Net cash flows arising from financing
activities
-316805707.84 267048993.41
IV. Influence on cash and cash -314517.97
equivalents due to fluctuation in
exchange rate
V. Net increase of cash and cash
equivalents
-132111911.47 -192908509.58
Add: Balance of cash and cash
equivalents at the period -begin
1776696342.87 1342041409.86
VI. Balance of cash and cash
equivalents at the period -end
1644584431.40 1149132900.28
II. Audit report
Whether the 3rd quarterly report has been audited or not
□Yes √ No
The 3rd quarterly report of the Company has not been audited.
沪公网安备31011802005267号
